Autoimmune Disease patents
This page is updated frequently with new Autoimmune Disease-related patent applications.
| Fluorometric immunoassay for detection of anti-dsdna antibodies|
The present invention relates to the field of immunological methods, more precisely to the field of detection methods for antibodies against double-stranded dna (dsdna) for diagnostics of chronic autoimmune diseases, such as systemic lupus erythematosus (sle). The fluorometric immunoassay method for detection of anti-dsdna solves the technical problem of designing a method for detection of the aforesaid antibodies, which would be faster, cheaper and less toxic as the standard farr-ria method, but would have the same diagnostic specificity (which is 100%) and improved diagnostic sensitivity (for 3%).
Univerzitetni Klinicni Center Ljubljana
| Tlr3 binding agents|
The present invention relates to antibodies (e.g. Monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind tlr3, and that optionally further modulate, e.g.
| Compositions and methods of use for therapeutic antibodies|
The present invention relates to antibodies that specifically bind to the baff receptor (baffr). The invention more specifically relates to specific antibodies that are baffr antagonists with in vivo b cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting b cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas..
| Method of inhibiting metastasis of cancer cells and modulating autoimmune diseases using gal-3bp-fc fusion protein|
A tgal-3bp-fc fusion protein, a pharmaceutical composition, an isolated nucleic acid, a recombinant expression vector, and a method of inhibiting, decreasing, reducing, suppressing or limiting metastasis of cancer cells, and immunosuppressing or modulating phagocytosis and t-cell functions by using the same are disclosed herein. The tgal-3bp-fc fusion protein comprises: a truncated gal-3 binding protein with domain 4, and at least an fc fragment of an immunoglobulin g.
Show-chwan Memorial Hospital
| Cytokine receptor peptides, compositions thereof and methods thereof|
The invention provides a pharmaceutical composition including a peptide comprising at least a portion of a chemokine receptor or a g-protein coupled receptor and optionally a cytokine. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis and asthma.
Symthera Canada Ltd.
| Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same|
There may be provided compositions of lipophilic pharmaceutical agents with improved solubility and stability. For example, there may be provided a non-aqueous composition that comprises a lipophilic pharmaceutical agent, and an amphiphilic polymeric solvent such as peg400 but essentially free of organic solvents and non-solubilized particles.
|Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor|
Benzoimidazol-2-yl pyrimidines, purification methods for the same, and pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritus.. .
Janssen Pharmaceutica Nv
|S-substituted quinazolines and their therapeutic applications for the treatment of diseases mediated by pde7|
The present invention relates to a family of s-substituted quinazoline derivatives that inhibitors of the enzyme phosphodiesterase 7 (pde7), useful for the treatment or prevention of diseases mediated by said enzyme, especially inflammatory, neurodegenerative, neurological, psychiatric and/or autoimmune diseases.. .
Consejo Superior De Lnvestigaciones Cientificas (csic)
|Compositions and methods for treating autoimmune and inflammatory diseases|
Compositions and methods are provided for the treatment and/or prevention of an inflammatory and/or autoimmune disease or disorder.. .
Trustees Of The Uniersity Of Pennsylvania
|Particle formulations of all-trans retinoic acid and transforming growth factor beta for the treatment of type 1 diabetes mellitus|
Particle formulations are disclosed that include polymeric particles containing a small molecule drug and a high molecular weight therapeutic protein. Methods of making and using the particle formulations also are disclosed.
Antigen-specific immunotherapy using tolerizing liposomes
The invention relates to a pharmaceutical composition for the treatment of allergic and autoimmune diseases by in vivo generation of tolerogenic dendritic cells (dcs) and macrophages using tolerizing liposomes loaded with at least one maturation inhibitor of dcs and at least one antigen or allergen or peptide derived thereof, made of at least one preparation, and comprising a matrix suitable for locally restricted sustained release of therapeutically effective doses of therapeutics including tolerogenic liposomes tailored for effective phagocytosis, at least one immune modulator of phagocytosis, and optionally at least one immune modulator suitable for enhancing the suppressive function of regulatory t cells and/or inhibiting the production of pro-inflammatory cytokines, and/or inhibiting the biological activity of secreted pro-inflammatory cytokines at the site of antigen or allergen presentation.. .
The present invention provides a liposome encapsulating an autoantigen, wherein the liposome has a size comprised from 500 to 15000 nm and the liposome membrane comprises phosphatydilserine (ps) in an amount comprised from 10 to 40% by weight with respect to the total membrane liposomal composition. Pharmaceutical or veterinary compositions comprising a therapeutically effective amount of said liposome are also provided.
InstituciÓ Catalana De Recerca I Estudis AvanÇats
Method for identifying disease-associated cdr3 patterns in an immune repertoire
The present disclosure generally pertains to a method for developing diagnostic tests that are based on the immune response and the resulting immune repertoire. The presently disclosed method increases the signal and reduces the background to allow the identification of shared cdr3s that can be used to produce a disease signature.
Cb Biotechnologies, Inc.
Nucleic acid capable of inhibiting expression of beta-2gpi
The present invention provides a nucleic acid having activity to suppress expression of β2gpi, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as aps, sle and the like and thrombosis in hemodialysis.. .
Kyowa Hakko Kirin Co., Ltd.
Baff selective binding compounds and related methods
The present invention relates to peptide antagonists that bind with high specificity and affinity to b-lymphocyte stimulator (“baff”), thereby antagonizing baff receptor (“baff-r”) signaling. The invention more specifically relates to vnar single chain antibodies derived from nurse shark that bind to baff, baff antagonist compounds and compositions comprising a baff specific vnar binding moiety, methods for preparing them, diagnostic and therapeutic methods of use relating to in vitro or in vivo b cell depletion, e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to kill or deplete b cells, such as in autoimmune diseases including systemic lupus erythematosus (sle), rheumatoid arthritis (ra) or multiple sclerosis (ms), and in certain hematological cancers, including lymphomas, leukemias and myelomas..
Antigenic gm-csf peptides and antibodies to gm-csf
Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided.
Heterocyclic compounds and their uses
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
The present invention relates to compositions and methods for improving a subject condition by epicutaneous immunobalancing. The invention shows that particular regulatory t cells can be induced and maintained in a subject by epicutaneous treatment, thereby causing a substantial improvement in a subject condition.
Tnfa-il-17 bispecific antibodies
Bispecific tetravalent antibodies against il-17 and tnfa, useful in therapy, e.g. The treatment of rheumatoid arthritis and other autoimmune diseases and/or to reduce pathological inflammatory conditions..
Hoffmann-la Roche Inc.
Diagnostic detecting a gaba(a) related autoimmune disease and related subject-matter
The present invention provides a use of a gaba(a)r, gaba(a)r fragment, or homolog thereof or a cell expressing the gaba(a)r, gaba(a)r fragment, or homolog thereof for the prognosis, diagnosis or treatment of an autoimmune disease in a subject, methods of prognosticating, diagnosing or treating an autoimmune disease, an autoantibody binding to a gaba(a)r, gaba(a)r fragment, or homolog thereof, a method for isolating an antibody binding to a gaba(a)r, gaba(a)r fragment, or homolog thereof, and a test kit, pharmaceutical composition and medical or diagnostic device comprising a gaba(a)r, gaba(a)r fragment, or homolog thereof.. .
Institucio Catalana De Recerca I Estudis Avancats
Derivatives of tartaric acid
The present invention relates to novel compounds, e.g. For use as a medicament.
Use of cd83 in combination therapies
The present invention relates to improved methods of suppressing and/or preventing an undesired immune response comprising the use of cd83. In some embodiments, cd83 is coadministered to a subject with at least one other immunosuppressive compound.
Argos Therapeutics, Inc.
Supplement for improving immunotolerance, intestinal environment and intestinal tract barrier
A supplement for improving immunotolerance, intestinal environment and intestinal tract barrier for the purpose of improving intestinal vulnerability, food intolerance or allergy, systemic allergy, autoimmune diseases and systemic inflammatory diseases by immune reactions which is obtained by mixing an ingredient (a) comprising at least one of a probiotic that is any one of lactic acid bacteria, lactobacillus bifidus, saccharified bacteria, natto bacteria and yeast fungus, or a mixture thereof, a biogenic that is a bacteria-producing substance such as lactic acid bacteria, and a prebiotic is indigestible food ingredients such as oligosaccharide, dietary fiber, substance stimulating production of lactobacillus bifidus, and others or a mixture thereof and an ingredient (b) comprising at least one of l-glutamine, zinc, vitamin a and vitamin d.. .
Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of btk, mtor kinase, and bcl-2 or their signaling pathways, and immunomodulatory drugs.
Zhejiang Dtrm Biopharma Co. Ltd.
Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells
A method of preferentially delivering an active agent to an immune cell, such as a myeloid progenitor cell, a dendritic cell, a monocyte, a macrophage or a t-lymphocyte, or other cell type restricted to a functional organ system or an anatomic entity, of a mammalian subject by administering a lipid-drug complex to the subject. The lipid-drug complex is comprised of an active agent, such as a drug, and an outer surface with a targeting ligand that binds a marker on the surface of the immune cell or other cell type that is infected with or susceptible to infection with an infectious agent.
Rodos Biotarget Gmbh
Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles
And pharmaceutically acceptable derivatives thereof. Methods of treatment of neoplastic and autoimmune diseases with these compounds are also disclosed..
The present invention provides humanized, chimeric and human anti-cd19 antibodies, anti-cd19 antibody fusion proteins, and fragments thereof that bind to a human b cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various b-cell disorders, including b-cell malignancies and autoimmune diseases.
Particles containing phospholipids or bioactive fatty acids and uses thereof
The subject matter disclosed herein is directed to particles containing phospholipids and/or fatty acids and the uses thereof for treating autoimmune diseases, inflammatory diseases and for modulating immune and inflammatory responses. Methods of preparing the particles are also described..
The University Of North Carolina At Chapel Hill
Substituted anilines as ccr(4) antagonists
Aniline compounds are provided which bind to ccr(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.. .
Halofuginone analogs for inhibition of trna synthetases and uses thereof
The present invention provides novel analogs and derivatives of halofuginone. The invention also provides pharmaceutical and cosmetic compositions thereof and methods for using halofuginone analogs in treating chronic inflammatory diseases, autoimmune diseases, dry eye syndrome, fibrosis, scar formation, angiogenesis, viral infections, ischemic damage, transplant and implant rejection, neurodegenerative diseases, and cosmetic applications..
Children's Medical Center Corporation
Autoimmune Disease topics:
Follow us on Twitter
This listing is a sample listing of patent applications related to Autoimmune Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.